Comparative Pharmacology
Head-to-head clinical analysis: HALOG E versus U CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOG E versus U CORT.
HALOG-E vs U-CORT
Head-to-head clinical comparison of therapeutic indices and safety profiles.
HALOG-E (halcinonide) is a corticosteroid that binds to glucocorticoid receptors, inducing the synthesis of lipocortin, which inhibits phospholipase A2, thereby reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
Corticosteroid-responsive dermatoses (e.g., atopic dermatitis, psoriasis, eczema)
Adrenocortical insufficiencyCongenital adrenal hyperplasiaSevere allergic reactionsInflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis)Off-label: Septic shock (stress-dose steroids), COVID-19-related inflammationTopical: Dermatitis, eczema, psoriasis
Apply a thin film to affected area twice daily. Initial therapy may be occlusive. Max 60 g/week.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life 8-14 hours, prolonged in hepatic impairment; clinical effect persists 24-36 hours due to tissue retention.
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Hepatic metabolism via CYP3A4; topical absorption can lead to systemic metabolism.
Hydrocortisone is primarily metabolized in the liver via 11β-hydroxysteroid dehydrogenase and 5α/5β-reductase, with CYP450 enzymes (e.g., CYP3A4) playing a minor role. Metabolites are excreted renally.
Renal (primarily as conjugates, 60-80%), fecal (15-30%), less than 5% unchanged in urine. Biliary excretion contributes to fecal elimination.
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Approximately 99% bound, primarily to corticosteroid-binding globulin (CBG) and albumin.
Approximately 85-90% bound, primarily to corticosteroid-binding globulin (CBG) and albumin.
Vd approximately 0.3-0.5 L/kg, indicating extensive tissue distribution and high affinity for glucocorticoid receptors.
Vd ~0.5 L/kg, indicating distribution into total body water, with minimal sequestering in deep compartments.
Topical: percutaneous absorption varies with skin condition; approximately 1-7% in intact skin, increases up to 36% in inflamed or abraded skin. Not administered orally or parenterally; thus, bioavailability by other routes is not applicable.
Topical: <5% systemic bioavailability through intact skin; increased with occlusion or damaged skin.
No adjustment required.
No dose adjustment required for renal impairment.
No adjustment required.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75%.
Not recommended for use in pediatric patients due to higher skin surface-to-body weight ratio and increased systemic absorption.
1-2 mg/kg intravenous bolus, then 0.5-1 mg/kg intravenously every 6 hours; maximum 100 mg per dose.
Use with caution; apply sparingly to limited areas. Avoid prolonged use, occlusive dressings, and use over large body surface areas.
Use lowest effective dose; monitor for hyperglycemia, hypertension, and osteoporosis. No specific dose adjustment required based on age alone.
None
There is no FDA black box warning specific to hydrocortisone. However, systemic corticosteroids are associated with increased risk of serious infections, adrenal suppression, and Cushing's syndrome with prolonged use.
["Systemic absorption may cause reversible HPA axis suppression, especially in children and with prolonged use on large areas.","Avoid use on face, groin, or axillae due to increased risk of atrophy.","Topical corticosteroids may increase risk of skin infections and mask signs of infection.","Use with caution in patients with hepatic impairment due to altered metabolism."]
May cause adrenal suppression, immunosuppression, osteoporosis, glaucoma, cataracts, hypertension, hyperglycemia, and growth retardation in children. Avoid abrupt discontinuation after prolonged use. Use with caution in infections, peptic ulcer disease, and hypothyroidism.
["Hypersensitivity to halcinonide or any component of the formulation","Untreated bacterial, fungal, or viral skin infections"]
Systemic fungal infections, known hypersensitivity to hydrocortisone, live or attenuated virus vaccines (high doses), and idiopathic thrombocytopenic purpura (intramuscular use).
Data Pending Review
Data Pending Review
No known food interactions.
Avoid grapefruit and grapefruit juice as they may increase hydrocortisone levels. Limit sodium and high-sugar foods to manage fluid retention and blood glucose. Take with food to reduce GI irritation.
FDA Pregnancy Category C. In first trimester, risk of cleft palate and cardiac malformations based on animal studies; human data limited. Second and third trimesters: risk of fetal adrenal suppression, intrauterine growth restriction, and preterm labor. Use only if benefit outweighs risk.
U-CORT (hydrocortisone) is a corticosteroid. First trimester: Increased risk of cleft palate (odds ratio ~3.4) with systemic use; topical use minimal systemic absorption considered low risk. Second/third trimester: Chronic use associated with fetal growth restriction, adrenal suppression, and preterm birth. Avoid high doses near term.
Excreted in breast milk; M/P ratio unknown. Potential for adrenal suppression in breastfeeding infant. Use caution; avoid high doses or prolonged use while nursing.
Hydrocortisone: M/P ratio 0.2-0.5; excreted in breast milk in low amounts. Use caution with high doses; may suppress infant adrenal function. Endogenous hydrocortisone equivalent to physiologic replacement considered safe.
No standard dose adjustment; use lowest effective dose for shortest duration. Increased corticosteroid metabolism in pregnancy may require higher doses for efficacy, but avoid excessive exposure.
Increased plasma volume and metabolism may require dose increase by 20-50% in second/third trimester. Monitor clinical response and increase as needed; taper after delivery.
Category C
Category C
Halobetasol propionate 0.05% is a super-high-potency topical corticosteroid. Limit use to ≤2 weeks; avoid on face, groin, axillae, or under occlusion. Monitor for HPA axis suppression with large surface area use.
U-CORT (hydrocortisone) is a corticosteroid used for anti-inflammatory and immunosuppressive effects. Administer with food to reduce GI irritation. Avoid abrupt discontinuation; taper dose. Monitor for adrenal suppression, hyperglycemia, and electrolyte imbalances. Use lowest effective dose for shortest duration.
Apply a thin layer only to affected skin areas.Do not use for more than 2 consecutive weeks.Avoid contact with eyes, face, groin, or under diapers.Do not cover with bandages or wraps unless directed.Wash hands after application unless hands are being treated.
Take with food or milk to prevent stomach upset.Do not stop taking this medication suddenly; follow your doctor's tapering schedule.Report any signs of infection (fever, sore throat), unusual weight gain, or mood changes.Avoid live vaccines while on this medication.Carry a medical alert card indicating you are on corticosteroids.